Global Nephroblastoma Treatment Market, by Type (Favorable histology and Anaplastic histology), by Drug Type (Dactinomycin (Cosmegen), Doxorubicin (Adriamycin), Vincristine (Vincasar PFS, Oncovin), Cyclophosphamide (Cytoxan, Neosar), Etoposide (Toposar, VePesid), Irinotecan (Camptosar), and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,653.0 Million in 2022 and is expected to exhibit a CAGR of 4.6% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing efforts by organizations working for the wellness of children with cancer to educate and train people about nephroblastoma is expected to drive the market growth over the forecast period. For instance, International Society of Pediatric Oncology (SIOP) is a global multidisciplinary society devoted to pediatric and adolescent cancer. The mission of the organization is to improve the lives of children and adolescents with cancer through global collaboration, education, training, research and advocacy
Global Nephroblastoma Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic
The COVID-19 pandemic had a negative impact on the nephroblastoma treatment market, owing to its impact on the diagnosis, treatment, and research of cancer. For instance, according to an article published by Dove Press Ltd, an academic publisher of open access peer-reviewed scientific and medical journals, in September 2021, the shortage of medical staff due to the admission of a large number of COVID-19 patients reduced the interaction frequency between patients and oncologists by 20% in the U.S., which postponed more than 22 million malignant tumor screening tests.
Browse 41 Market Data Tables and 43 Figures spread through 156 Pages and in-depth TOC on “Global Nephroblastoma Treatment Market”- Forecast to 2030, Global Nephroblastoma Treatment Market, by Type (Favorable histology and Anaplastic histology), by Drug Type (Dactinomycin (Cosmegen), Doxorubicin (Adriamycin), Vincristine (Vincasar PFS, Oncovin), Cyclophosphamide (Cytoxan, Neosar), Etoposide (Toposar, VePesid), Irinotecan (Camptosar), and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the global prebiotics for Global Nephroblastoma Treatment Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/nephroblastoma-treatment-market-5192
The release of guidelines for the diagnosis of nephroblastoma is expected to drive the market growth over the forecast period. For instance, in February 2021, the National Comprehensive Cancer Network (NCCN) published its first set of treatment guidelines for nephroblastoma, a rare type of pediatric kidney cancer commonly known as wilms tumor. Molecular testing to risk stratify patients was a key focus of the NCCN guidelines. Specifically, the NCCN recommended performing cytogenic and molecular testing at the point of diagnosis for all wilms tumor patients with favorable histology, which comprises the majority of these cancers.
Key Takeaways of the Global Nephroblastoma Treatment Market:
- The global nephroblastoma treatment market is expected to exhibit a CAGR of 4.6% during the forecast period due to the increasing research and development activities by universities to develop and study treatment options for nephroblastoma. For instance, New York Medical College is as of August 4, 2022 testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide to find a drug that may be effective against tumors including wilms tumor that have come back or that have not responded to standard therapy. The study as of August 4, 2022 is in phase 1 of its clinical trial and the study is estimated to be completed by December 2022.
- On the basis of types, the favorable histology segment is estimated to dominate the market growth in 2022. For instance, according to an article published by the National Center for Biotechnology Information, in May 2022, ninety percent of wilms tumors demonstrate favorable histology, which generally has a better prognosis.
- Among distribution channels, the hospital pharmacies segment is expected to dominate the market over the forecast period, owing to the increased rate of hospitalizations associated with the disease. Nephroblastoma or wilms tumor requires surgery as part of their treatment plan, which can increase the rate of hospitalization.
- Major players operating in the global nephroblastoma treatment market include Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals
